Suchergebnisse - "Hawkes, Carol"

PubPharm (9)

1

Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer

enthalten in: Future oncology (London, England) | 2022

von Guy, H. | Hawkes, C. | Walder, L. | +2

2

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer

enthalten in: Cancers | 2022

von Lorusso, D. | Guy, H. | Samyshkin, Y. | +3

3

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

enthalten in: Therapeutic advances in medical oncology | 2022

von Barretina-Ginesta, M. | Monk, B. | Han, S. | +17

4

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective

enthalten in: Journal of managed care & specialty pharmacy | 2021

von Liu, J. | Hawkes, C. | Walder, L. | +4

5

Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis

enthalten in: Journal of patient-reported outcomes | 2021

von Becker, B. | Raymond, K. | Hawkes, C. | +6

6

Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis

enthalten in: Journal of patient-reported outcomes | 2021

von Becker, B. | Raymond, K. | Hawkes, C. | +6

7

Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis

enthalten in: Journal of patient-reported outcomes | 2021

von Becker, B. | Raymond, K. | Hawkes, C. | +6

8

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis : a randomised, phase 2b, dose-ranging study

enthalten in: The Lancet. Rheumatology | 2020

von Buckley, C. | Simón-Campos, J. | Zhdan, V. | +12

ErratumIn: Lancet Rheumatol. 2021 Apr;3(4):e250. - PMID 38279409

9

Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer

enthalten in: Breast care (Basel, Switzerland) | 2013

von Delea, T. | Hawkes, C. | Amonkar, M. | +2

1
[1]